Vindesine Sulfate
Brand names,
Vindesine Sulfate
Analogs
Vindesine Sulfate
Brand Names Mixture
Vindesine Sulfate
Chemical_Formula
C43H55N5O7
Vindesine Sulfate
RX_link
http://www.rxlist.com/cgi/generic2/vinor_cp.htm
Vindesine Sulfate
fda sheet
Vindesine Sulfate
msds (material safety sheet)
Vindesine Sulfate
Synthesis Reference
G. J. Cullinan, K. Gerzon, Ger. pat. 2,415,980 (1974 to Lilly)
Vindesine Sulfate
Molecular Weight
753.926 g/mol
Vindesine Sulfate
Melting Point
230-232 oC
Vindesine Sulfate
H2O Solubility
No information avaliable
Vindesine Sulfate
State
Solid
Vindesine Sulfate
LogP
4.002
Vindesine Sulfate
Dosage Forms
IM solution; Powder for solution
Vindesine Sulfate
Indication
For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
Vindesine Sulfate
Pharmacology
Vindesine is indicated for the treatment of acute lymphocytic leukemia of childhood that is resistant to vincristine and non-oat cell lung cancer.Vindesine causes the arrest of cells in metaphase mitosis. It is three times more potent than vincristine and nearly 10 times more potent than vinblastine in causing mitotic arrest in in vitro studies at doses designed to arrest from 10 to 15% of the cells in mitosis. Vindesine and vincristine are approximately equipotent at dose levels that arrest 40 to 50% of the cells in mitosis. Unlike vinblastine, vindesine produces very few postmetaphase cells. Vindesine has demonstrated activity in patients who have relapsed while receiving multiple-agent treatment that included vincristine.
Vindesine Sulfate
Absorption
No information avaliable
Vindesine Sulfate
side effects and Toxicity
No information avaliable
Vindesine Sulfate
Patient Information
Patient Information:
The treatmewnt with Vindesine can cause hair, but it is usually reversible. It may also cause
loss of sensation or tingling in hands or feet, fever, chill, sore throat, constipation, black
stool, bruising or bleeding.
Patients should be informed that the major acute toxicities of Vindesine are related to bone
marrow toxicity, specifically granulocytopenia with increased susceptibility to infection.
They should be advised to report fever or chills immediately. Women of childbearing potential
should be advised to avoid becoming pregnant during treatment. Patients should be advised to
contact their physician if they experience increased shortness of breath, cough, or other new
pulmonary symptoms, or if they experience symptoms of abdominal pain or constipation.
Vindesine Sulfate
Organisms Affected
Humans and other mammals